Muhammad Mohsin Khan

Muhammad Mohsin Khan

Auto-generated profile, based on publicly available information

Muhammad Mohsin Khan

Jinnah Sindh Medical University, Karachi, Pakistan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2025 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
HMHaleema Mansoor
Haleema Mansoor
MGMaheen Gohar
Maheen Gohar
AAAsma Attaria
Asma Attaria
FKFaiza Fatima Karim
Faiza Fatima Karim
UNUmaimah Naeem
Umaimah Naeem
JIJaved Iqbal
Javed Iqbal
Gastric cancer, especially cancer of the gastro-esophageal junction, ranks among the first five cancers in the world with the highest mortality rates. It has poor survival rates for the advanced stages. Traditional chemotherapy, while standard, often results in significant side effects and limited efficacy. The objective of this meta-analysis and systemic review is to ascertain if pembrolizumab-based therapies for advanced gastric cancer are more effective and safer than standard chemotherapy. The focus consisted of RCTs with adults suffering from gastric carcinoma who received pembrolizumab every 3 weeks (200 mg) intra-related dose or with at least comparable chemotherapy regimen. Outcomes assessed are as follows: overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). All potential sources regarding the search of outcome measures were applied: Google Scholar, Scopus, PubMed, and Cochrane library, and last search in June 2024 was carried out. Out of 568 articles screened, four RCTs comprising 2,831 patients met the inclusion criteria. Analysis indicated that pembrolizumab alone did not significantly improve OS compared to chemotherapy (HR 0.87). However, when combined with chemotherapy, pembrolizumab dramatically enhanced OS (HR 0.80) and PFS (HR 0.78). ORR was superior in the pembrolizumab plus chemotherapy group (RR 1.24), while pembrolizumab monotherapy showed no significant difference from chemotherapy alone. Safety analysis revealed a higher frequency of adverse events in the pembrolizumab-based therapy groups compared to chemotherapy. Pembrolizumab together with chemotherapy improves greater survival and higher levels of response rate in patients with severe gastric cancer, especially with high PD-L1 expression. But it has rather more adverse events, allowing patient monitoring with care.

1 December 2025 in Microbiologyopen
Verified
Journal Article
Open access
AAAsma Azam
Asma Azam
MQMuhammad Abdul Muqtadir Qureshi
Muhammad Abdul Muqtadir Qureshi
HZHafiz Shahbaz Zahoor
Hafiz Shahbaz Zahoor
SRSyeda Malaika Raza
Syeda Malaika Raza
MKMuhammad Mohsin Khan
Muhammad Mohsin Khan
AWAbdul Waheed
Abdul Waheed
Supplementing H. pylori treatment with probiotics like Lactobacillus has become an essential approach due to the possible adverse effects of antibiotic therapy and the need to increase overall eradication rates. Although several types of Lactobacillus strains as probiotics were efficient in treating H. pylori , their relative efficiency in treating H. pylori was uncertain. A survey of databases, including PubMed, Cochrane, Google Scholar, Scopus, and Clinicaltrials.gov , retrieved 52 Randomized Controlled Trials (RCTs), with 14 meeting the criteria for RCTs on Lactobacillus supplementation (LS) as an adjunct therapy compared to placebo in adult H. pylori patients. Analyses were conducted using RevMan5.3, Cochrane Risk of Bias Tool, Comprehensive Meta‐Analysis Software, and GRADEpro. Fourteen RCTs, including 2054 patients with more than ten different probiotics, were included in this analysis. The LS group showed significantly higher H. pylori eradication rates [RR = 1.04 (95% CI: 1.01, 1.07; p = 0.009; I 2 = 0%); (high certainty)], decreased AEs including vomiting [RR = 0.82 (95% CI: 0.48, 1.41; p = 0.48; I 2 = 19%); (high certainty)], diarrhea [RR = 0.45 (95% CI: 0.26, 0.80; p = 0.007; I ² = 55%); (high certainty)], abdominal pain [RR = 0.73 (95% CI: 0.28, 1.93; p = 0.53; I ² = 66%); (high certainty)], anorexia [RR = 0.79 (95% CI: 0.23, 2.64; p = 0.70; I ² = 0%); (high certainty)], constipation [RR = 1.02 (95% CI: 0.42, 2.50; p = 0.96; I ² = 0%); (high certainty)], rash [RR = 1.51 (95% CI: 0.57, 3.98; p = 0.41; I ² = 0%); (high certainty)], taste disturbance [RR = 0.64 (95% CI: 0.44, 0.92; p = 0.02; I ² = 51%); (moderate certainty)], and reduction of gastrointestinal symptoms including abdominal pain [SMD = −0.19 (95% CI: −0.46, 0.09; p = 0.18; I² = %); (moderate certainty)]. None of the included RCTs depicted a high risk of bias. Lactobacillus added to triple or quadruple therapy increased eradication rates, but improvements in adverse effects and gastrointestinal symptoms were not significant. Multiple different strains limited assessment of individual effectiveness, preventing firm conclusions about the specific impact of each Lactobacillus type.

5 June 2025 in Therapeutic Advances in Vaccines and Immunotherapy
Verified
Journal Article
Open access
ESErum Siddiqui
Erum Siddiqui
MKMohammad Saad Khan
Mohammad Saad Khan
MKMaliha Khalid
Maliha Khalid
HCHarshika Khaim Chandani
Harshika Khaim Chandani
UNUmaimah Naeem
Umaimah Naeem
SWSyed Owais Wasti
Syed Owais Wasti
Background: Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is an ancient disease that continues to pose a significant threat to global public health. Although the BCG vaccine, developed in the 1920s, remains the only approved TB vaccine, it has limited efficacy, particularly against pulmonary TB in adults. The ID93/GLA-SE vaccine, a recombinant subunit vaccine, shows promise by triggering immune solid responses and could be a key solution in combating TB, particularly in the face of rising drug-resistant strains and suboptimal current vaccines. It has the potential to address the unmet need for more effective interventions against drug-resistant TB, a growing global health issue that continues to challenge existing treatment options. Objective: To evaluate the immunogenicity and safety of ID93 + GLA-SE in BCG-vaccinated healthy adults. Methods: A comprehensive electronic search on PubMed (Medline), ScienceDirect, EMBASE, Scopus, and Cochrane Central database was conducted from inception till August 2024 for randomized controlled trials (RCTs) with a target population of BCG-vaccinated healthy adults. This review was conducted according to (PRISMA) criteria and registered with PROSPERO (CRD42024601450). This meta-analysis used Review Manager and forest plots for visual display. The outcomes were displayed as risk ratios (RR) with a 95% confidence interval. Results: The ID93 + GLA-SE vaccine showed strong immunogenicity, particularly in high doses, with robust IgG responses sustained up to day 421 in all studies, significantly higher than baseline, and seroconversion rates remained high through day 84. CD4 T-cell responses peaked after the third dose and remained elevated through day 421, whereas CD8 T-cell responses were minimal. Regarding adverse effects, the ID93 + GLA-SE vaccine significantly increases fatigue (RR 3.24, p = 0.005), myalgia (RR 5.82, p < 0.0001), and injection site pain (RR 4.12, p < 0.00001), compared to placebo, with consistent results across both high and low doses. However, there were no significant differences for upper respiratory tract infections, 0.83 (95% CI 0.38–1.84, p = 0.87) or 1.77 (95% CI 0.77–4.10, p = 0.18) headaches. Dose optimization remains crucial due to the higher side effect risks of increased doses. Conclusion: The ID93 + GLA-SE vaccine shows a solid safety profile and enhances immune responses, especially IgG and CD4+ T-cell activity, which is crucial for TB defense. Higher doses improve efficacy but increase side effects, highlighting the need for dose optimization. As a potential alternative to the BCG vaccine, especially in drug-resistant TB regions, further research should refine dosage and assess long-term safety.

23 March 2026 in Health Science Reports
Verified
Journal Article
Open access
PDF file
LALaiba Akram
Laiba Akram
MKMuhammad Saad Khan
Muhammad Saad Khan
UNUzma Naseeb
Uzma Naseeb
ZAZarmeen Azhar
Zarmeen Azhar
ZAZunnerah Akram
Zunnerah Akram
AMAbubakr Mahmoud
Abubakr Mahmoud
Background and Aims: Non‐communicable diseases (NCDs) cause about 70% of global deaths, and early detection through routine medical checkups (RMCs) is a key preventive measure. Despite their importance, RMC uptake remains low, particularly among youth. This study assessed the knowledge, practices, and perceptions of RMCs among medical students in Karachi, Pakistan, and identified barriers to their participation. Methods: A descriptive cross‐sectional study was conducted from May to July 2025 across four medical institutions in Karachi, including JSMU, DUHS, KMDC, and SMBBMC. A total of 246 MBBS students from third to final year were selected via non‐probability convenience sampling. Ethical approval was obtained from JSMU′s Institutional Review Board (IRB No. JSMU/IRB/2025/1025). Data were collected through a structured, pilot‐tested electronic questionnaire assessing independent variables (age, gender, year of study, knowledge, attitudes, and perceived barriers) and outcome variables (practice of RMCs). Cronbach′s alpha for knowledge and practice domains was 0.76 and 0.72, respectively. Data were analyzed using SPSS v26, employing descriptive statistics, independent t‐tests, and ANOVA at a significance level of p < 0.05. Results: Among 246 respondents, 83% were female and the majority (77.2%) were aged 21–23 years. While 90.2% correctly identified the preventive purpose of RMCs, only 21.4% personally scheduled checkups when asymptomatic. Most students (89.9%) supported including mental health screenings in RMCs. Female gender, age group, and year of study were not significantly associated with knowledge scores ( p ≥ 0.05). Major barriers included lack of awareness (27.2%), financial constraints (25.8%), and fear of discovering illness (16%). Although 80.4% had recommended RMCs to others, only 26.8% had undergone a checkup within the past year. Conclusion: Despite good theoretical knowledge and positive attitudes toward RMCs, actual practice among medical students remains poor. Financial barriers, perceived invulnerability, and time constraints hinder participation. Integrating preventive health practices into the curriculum, along with awareness campaigns and affordable services, may bridge the knowledge–practice gap.

14 May 2025 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
ESErum Siddiqui
Erum Siddiqui
MKMaliha Khalid
Maliha Khalid
MKMuhammad Saad Khan
Muhammad Saad Khan
KFKanza Farhan
Kanza Farhan
MKMuhammad Mohsin Khan
Muhammad Mohsin Khan
AWAminath Waafira
Aminath Waafira
Background: Hemophilia A and B are X-linked recessive bleeding disorders caused by deficiencies of coagulation factors VIII and IX, respectively. These conditions lead to spontaneous bleeding, joint damage, inhibitor development, and the burden of frequent intravenous infusions. Concizumab, a monoclonal antibody targeting tissue factor pathway inhibitor (TFPI), is a novel non-factor therapy that enhances thrombin generation. This systematic review evaluates the efficacy and safety of concizumab prophylaxis in patients with hemophilia A and B. Methods: This systematic review was conducted in accordance with PRISMA guidelines. Randomized controlled trials (RCTs) assessing the use of concizumab in hemophilia A or B were identified through a comprehensive search of electronic databases. Outcomes of interest included annualized bleeding rate (ABR), thrombin generation, bleeding episodes, immunogenicity, and adverse events. The Cochrane Risk of Bias Tool 2.0 was used for quality assessment. Results: Five studies were included. Concizumab prophylaxis was associated with a notable reduction in ABR, with reported decreases from 9.4 to 1.3 episodes/year and from 19.6 to 2.9 episodes/year in hemophilia A, and from 14.9 to 1.6 episodes/year in hemophilia B. Thrombin generation increased in a dose-dependent manner and stabilized by week 24. Across all studies, bleeding episodes were significantly reduced. Adverse events were primarily mild to moderate. No thromboembolic events were reported. Conclusion: Concizumab appears to be an effective and safe prophylactic treatment for patients with hemophilia A and B, demonstrating consistent reductions in bleeding rates and enhanced thrombin generation. Further long-term studies are warranted to establish its sustained safety and efficacy.

1 July 2023 in Journal of Gandhara Medical and Dental Science
Verified
Journal Article
Open access
MKMohsin Khan
Mohsin Khan
NKNiama Khan
Niama Khan
MJMudassir Abdul Jalil
Mudassir Abdul Jalil
MAMuhammad Asfandiyar Ali
Muhammad Asfandiyar Ali
JKJawad Khan Khan
Jawad Khan Khan